Aliases & Classifications for Oppositional Defiant Disorder

MalaCards integrated aliases for Oppositional Defiant Disorder:

Name: Oppositional Defiant Disorder 12 77 56 6 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0050856
ICD10 34 F91.3
UMLS 74 C0029121

Summaries for Oppositional Defiant Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by a pattern of angry mood, defiant behavior and vindictiveness in children and adolescents.

MalaCards based summary : Oppositional Defiant Disorder is related to depression and anxiety, and has symptoms including photophobia, restlessness and personality changes. An important gene associated with Oppositional Defiant Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Circadian entrainment and Transmission across Chemical Synapses. The drugs Risperidone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Oppositional defiant disorder (ODD) is listed in the DSM-5 under Disruptive, impulse-control, and... more...

Related Diseases for Oppositional Defiant Disorder

Diseases related to Oppositional Defiant Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Related Disease Score Top Affiliating Genes
1 depression 31.0 MAOA SLC6A4 TPH2
2 anxiety 30.5 COMT MAOA SLC6A4 TPH2
3 separation anxiety disorder 30.5 DRD4 SLC6A3
4 bipolar disorder 30.2 COMT SLC6A3 SLC6A4
5 tic disorder 30.2 DRD4 SLC6A3 TPH2
6 conduct disorder 30.1 COMT DBH DRD4 MAOA SLC6A3 SLC6A4
7 stuttering 30.1 DBH SLC6A3
8 generalized anxiety disorder 29.6 COMT MAOA SLC6A2 SLC6A4
9 borderline personality disorder 29.6 COMT MAOA SLC6A4 TPH2
10 personality disorder 29.4 COMT DRD4 MAOA SLC6A3 SLC6A4
11 disease of mental health 29.4 COMT DRD4 MAOA SLC6A2 SLC6A3 SLC6A4
12 gilles de la tourette syndrome 29.4 COMT DBH DRD4 SLC6A3
13 attention deficit-hyperactivity disorder 29.4 COMT DBH DRD4 MAOA SLC6A2 SLC6A3
14 mood disorder 28.9 COMT DRD4 MAOA SLC6A2 SLC6A4 TPH2
15 alcohol dependence 28.3 COMT DBH DRD4 MAOA SLC6A3 SLC6A4
16 schizophrenia 27.9 COMT DBH DRD4 MAOA SLC6A2 SLC6A3
17 pol iii-related leukodystrophies 11.1
18 autism 10.6
19 autism spectrum disorder 10.5
20 pseudobulbar affect 10.3
21 dependent personality disorder 10.3 DRD4 MAOA
22 alcohol-induced mental disorder 10.2 SLC6A3 SLC6A4
23 avoidant personality disorder 10.2 MAOA SLC6A4
24 alcoholic psychosis 10.2 SLC6A3 SLC6A4
25 atypical depressive disorder 10.2 MAOA SLC6A4
26 social phobia 10.2 MAOA SLC6A4
27 premature ejaculation 10.2 SLC6A3 SLC6A4
28 dysthymic disorder 10.2 MAOA SLC6A4
29 kleptomania 10.2 MAOA SLC6A4
30 amphetamine abuse 10.2 SLC6A2 SLC6A3
31 serotonin syndrome 10.1 MAOA SLC6A4
32 migraine without aura 10.1 DRD4 SLC6A4
33 phobia, specific 10.1 COMT MAOA
34 brain injury 10.1
35 traumatic brain injury 10.1
36 reading disorder 10.1
37 hematohidrosis 10.1
38 dystonia 1, torsion, autosomal dominant 10.1 COMT MAOA
39 kleine-levin hibernation syndrome 10.1 COMT SLC6A3
40 endogenous depression 10.1 MAOA SLC6A4
41 alexithymia 10.0 COMT SLC6A4
42 fibromyalgia 10.0 COMT SLC6A4
43 agoraphobia 10.0 MAOA SLC6A2 SLC6A4
44 central nervous system disease 10.0 SLC6A2 SLC6A3 SLC6A4
45 bipolar i disorder 9.9 COMT SLC6A4
46 pure autonomic failure 9.9 DBH MAOA
47 sudden infant death syndrome 9.9 MAOA SLC6A4 TPH2
48 eating disorder 9.9 COMT SLC6A3 SLC6A4
49 phobic disorder 9.9 COMT MAOA SLC6A4
50 postpartum depression 9.9 COMT MAOA SLC6A4

Graphical network of the top 20 diseases related to Oppositional Defiant Disorder:



Diseases related to Oppositional Defiant Disorder

Symptoms & Phenotypes for Oppositional Defiant Disorder

UMLS symptoms related to Oppositional Defiant Disorder:


photophobia, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances

MGI Mouse Phenotypes related to Oppositional Defiant Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.92 COMT DBH DRD4 MAOA SLC6A2 SLC6A3
2 homeostasis/metabolism MP:0005376 9.76 COMT DBH DRD4 MAOA SLC6A2 SLC6A3
3 cardiovascular system MP:0005385 9.73 COMT DBH MAOA SLC6A2 SLC6A4 TPH2
4 integument MP:0010771 9.43 DBH NET1 SLC6A2 SLC6A3 SLC6A4 TPH2
5 nervous system MP:0003631 9.23 COMT DBH DRD4 MAOA SLC6A2 SLC6A3

Drugs & Therapeutics for Oppositional Defiant Disorder

Drugs for Oppositional Defiant Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 76)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
3
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 113-45-1 4158
4
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
5
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
6
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 3007 5826
7
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
8
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
9
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
10
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
14 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
15 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
16 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
17 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
18 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Not Applicable
21 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Anticonvulsants Phase 4
25 Antimanic Agents Phase 4
26 GABA Agents Phase 4
27 Atomoxetine Hydrochloride Phase 4,Phase 3
28 Adrenergic Agents Phase 4,Phase 3
29 Autonomic Agents Phase 4
30 Peripheral Nervous System Agents Phase 4
31 Sympathomimetics Phase 4
32 Adrenergic alpha-Agonists Phase 4
33 Adrenergic Agonists Phase 4
34 Antihypertensive Agents Phase 4
35 Adrenergic alpha-2 Receptor Agonists Phase 4
36 insulin Phase 4
37 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
38 Insulin, Globin Zinc Phase 4
39 Serotonin 5-HT1 Receptor Agonists Phase 4,Phase 3,Not Applicable
40 Serotonin Uptake Inhibitors Phase 4
41 Dopamine agonists Phase 4,Phase 3,Phase 1,Not Applicable
42 Serotonin Receptor Agonists Phase 4,Phase 3,Not Applicable
43 Dopamine D2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
44 Gastrointestinal Agents Phase 4
45 Serotonin 5-HT2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
46 Antiemetics Phase 4
47 Lisdexamfetamine Dimesylate Phase 4
48 Anesthetics, Local Phase 4
49 Anesthetics Phase 4
50
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
4 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
5 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
6 Metabolic Effects of Antipsychotics in Children Completed NCT00205699 Phase 4 risperidone;olanzapine;aripiprazole
7 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
8 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? Completed NCT01127607 Phase 4 lisdexamfetamine
9 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Completed NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
10 Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder Recruiting NCT02951754 Phase 4 Immediate-release Methylphenidate
11 Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention Recruiting NCT03279952 Phase 4 CNS Stimulant
12 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Not yet recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
13 Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD Terminated NCT02638168 Phase 4 Immediate Release Methylphenidate;Placebo
14 An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Completed NCT00192023 Phase 3 atomoxetine 0.5 mg/kg/day;placebo;atomoxetine 1.2 mg/kg/day;atomoxetine 1.2-1.4 mg/kg/day
15 Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD Completed NCT00191698 Phase 3 atomoxetine hydrochloride;placebo
16 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
17 Strongest Families Ontario (Formerly the Family Help Program) Completed NCT01473511 Phase 3
18 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
19 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
20 Omega-3 Supplementation and Behavior Problems Completed NCT02334098 Phase 2, Phase 3
21 Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders Completed NCT03627312 Phase 2, Phase 3
22 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
23 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
24 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
25 Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Completed NCT00402857 Phase 3
26 Brief Strategic Family Therapy for Adolescent Drug Abusers Completed NCT00095303 Phase 3
27 Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
28 Efficacy of Atomoxetine on Psychosocial Function of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00320528 Phase 3 atomoxetine
29 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 Edivoxetine
30 Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Completed NCT00676429 Phase 2 Ziprasidone Hydrochloride;Placebo
31 Home Based Treatment for Drug Use in Early Adolescents Completed NCT00280228 Phase 2
32 Quetiapine and Concerta in the Treatment for ADHD and Aggressive Behavior. Completed NCT00550147 Phase 2 Oros Methylphenidate;quetiapine
33 Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD) Completed NCT01725737 Phase 2 GlyTI-M;Placebo
34 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
35 Evaluating the Efficacy of Supplementation With Micronutrients in ADHD Youth Recruiting NCT03252522 Phase 1, Phase 2
36 Treatment of Conduct Problems and Depression Unknown status NCT01267773 Phase 1
37 Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders Completed NCT03292848 Phase 1 Brexpiprazole
38 Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions Unknown status NCT02409992 Not Applicable
39 Treatment of Children With Peer Related Aggressive Behavior (ScouT) Unknown status NCT02143427 Not Applicable
40 Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children Unknown status NCT00189189 Not Applicable
41 Guided Self-Help for Parents of Children With Externalizing Problem Behavior Unknown status NCT01350986 Not Applicable
42 Epidemiological Study for Psychiatric Disorder Among Children and Adolescents Unknown status NCT02707848
43 Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children Unknown status NCT02433145
44 Toolkit for School Behavior Modification in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) Unknown status NCT01330849 Not Applicable
45 Better Understand Children and Adolescents' Intrafamilial Oppositional Defiant Disorder Completed NCT03447535
46 Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder Completed NCT00510120 Not Applicable
47 Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth Completed NCT00404911 Not Applicable
48 On-line Treatment for Conduct Problems Completed NCT01822392 Not Applicable
49 Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits Completed NCT01362946 Not Applicable
50 Prevention of Child Mental Health Problems in Southeastern Europe Completed NCT03552250 Not Applicable

Search NIH Clinical Center for Oppositional Defiant Disorder

Genetic Tests for Oppositional Defiant Disorder

Anatomical Context for Oppositional Defiant Disorder

MalaCards organs/tissues related to Oppositional Defiant Disorder:

42
Brain, Testes, Eye, Thyroid, Cortex

Publications for Oppositional Defiant Disorder

Articles related to Oppositional Defiant Disorder:

(show top 50) (show all 302)
# Title Authors Year
1
High pretreatment cognitive impulsivity predicts response of oppositional symptoms to methylphenidate in patients with attention-deficit hyperactivity disorder/oppositional defiant disorder. ( 30640748 )
2019
2
Self-Reported and Parent-Reported School Bullying in Adolescents with High Functioning Autism Spectrum Disorder: The Roles of Autistic Social Impairment, Attention-Deficit/Hyperactivity and Oppositional Defiant Disorder Symptoms. ( 30925769 )
2019
3
Emotional valence detection in adolescents with oppositional defiant disorder/conduct disorder or autism spectrum disorder. ( 30680520 )
2019
4
A Comparative Study on the Effectiveness of Individual and Group Play Therapy on Symptoms of Oppositional Defiant Disorder among Children. ( 30625268 )
2019
5
The Parent-Child Relationship and Posttreatment Child Outcomes Across Two Treatments for Oppositional Defiant Disorder. ( 30730774 )
2019
6
Prevalence, comorbidity, functioning and long-term effects of subthreshold oppositional defiant disorder in a community sample of preschoolers. ( 30834986 )
2019
7
First incidence, age of onset outcomes and risk factors of onset of DSM-5 oppositional defiant disorder: a cohort study of Spanish children from ages 3 to 9. ( 30928923 )
2019
8
Are Sluggish Cognitive Tempo, ADHD, and Oppositional Defiant Disorder Trait- or State-Like Constructs from Prekindergarten to Fourth Grade? ( 30985190 )
2019
9
The Developmental Propensity Model Extends to Oppositional Defiant Disorder: a Twin Study. ( 31065860 )
2019
10
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? ( 26842831 )
2019
11
Age 4 Predictors of Oppositional Defiant Disorder in Early Grammar School. ( 28278601 )
2019
12
Child-based treatment of oppositional defiant disorder: mediating effects on parental depression, anxiety and stress. ( 29948233 )
2018
13
Impact of Drug Adherence on Oppositional Defiant Disorder and Conduct Disorder Among Patients With Attention-Deficit/Hyperactivity Disorder. ( 30192445 )
2018
14
The effect of methylphenidate treatment on psychopathic behavior of patients having attention-deficit hyperactivity disorder with and without oppositional defiant disorder. ( 29958238 )
2018
15
Junior temperament character inventory together with quantitative EEG discriminate children with attention deficit hyperactivity disorder combined subtype from children with attention deficit hyperactivity disorder combined subtype plus oppositional defiant disorder. ( 29787785 )
2018
16
Oppositional defiant disorder/conduct disorder co-occurrence increases the risk of Internet addiction in adolescents with attention-deficit hyperactivity disorder. ( 29865863 )
2018
17
Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals. ( 30201120 )
2018
18
Boys with Oppositional Defiant Disorder/Conduct Disorder Show Impaired Adaptation During Stress: An Executive Functioning Study. ( 28755013 )
2018
19
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
20
Oppositional Defiant Disorder dimensions and aggression: The moderating role of hostile bias and sex. ( 30009747 )
2018
21
Associations of serotonin transporter gene promoter polymorphisms and monoamine oxidase A gene polymorphisms with oppositional defiant disorder in a Chinese Han population. ( 30126429 )
2018
22
Narcissistic traits and self-esteem in children: Results from a community and a clinical sample of patients with oppositional defiant disorder. ( 30142585 )
2018
23
Change in Maternal Stress for Families in Treatment for their Children with Oppositional Defiant Disorder. ( 30294196 )
2018
24
Longitudinal linkages between parenting stress and oppositional defiant disorder (ODD) symptoms among Chinese children with ODD. ( 30321015 )
2018
25
Informant-specific reports of peer and teacher relationships buffer the effects of harsh parenting on children's oppositional defiant disorder during kindergarten. ( 30458890 )
2018
26
External validation of a bifactor model of oppositional defiant disorder. ( 30538308 )
2018
27
Preschool Oppositional Defiant Disorder: A Disorder of Negative Affect, Surgency, and Disagreeableness. ( 27768388 )
2018
28
Multiple Levels of Family Factors and Oppositional Defiant Disorder Symptoms Among Chinese Children. ( 27900762 )
2018
29
Testing Multiple Conceptualizations of Oppositional Defiant Disorder in Youth. ( 28287828 )
2018
30
Predictors of Partial Hospital Readmission for Young Children with Oppositional Defiant Disorder. ( 29164350 )
2018
31
Comparing the characteristics and outcomes of parent- and teacher-reported oppositional defiant disorder: findings from a national sample. ( 29230806 )
2018
32
Maltreatment and Affective and Behavioral Problems in Emerging Adults With and Without Oppositional Defiant Disorder Symptoms: Mediation by Parent-Child Relationship Quality. ( 29528803 )
2018
33
Structural Brain Abnormalities of Attention-Deficit/Hyperactivity Disorder With Oppositional Defiant Disorder. ( 28911901 )
2017
34
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. ( 28806385 )
2017
35
Risk factors for comorbid oppositional defiant disorder in attention-deficit/hyperactivity disorder. ( 28283834 )
2017
36
The Possible Effect of Methylphenidate Treatment on Empathy in Children Diagnosed with Attention-Deficit/Hyperactivity Disorder, Both With and Without Comorbid Oppositional Defiant Disorder. ( 28398816 )
2017
37
Effect of Methylphenidate on Emotional Dysregulation in Children With Attention-Deficit/Hyperactivity Disorder + Oppositional Defiant Disorder/Conduct Disorder. ( 28225747 )
2017
38
Memory consolidation of socially relevant stimuli during sleep in healthy children and children with attention-deficit/hyperactivity disorder and oppositional defiant disorder: What you can see in their eyes. ( 28049026 )
2017
39
Implicit emotion regulation: linking childhood oppositional defiant disorder with adult depression and bipolar disorder? ( 26536579 )
2017
40
Neurobiological stress responses predict aggression in boys with oppositional defiant disorder/conduct disorder: a 1-year follow-up intervention study. ( 28181041 )
2017
41
Oppositional Defiant Disorder Is Better Conceptualized as a Disorder of Emotional Regulation. ( 24481934 )
2017
42
The Reciprocal Influence of Callous-Unemotional Traits, Oppositional Defiant Disorder and Parenting Practices in Preschoolers. ( 27013514 )
2017
43
Emotional Abilities in Children with Oppositional Defiant Disorder (ODD): Impairments in Perspective-Taking and Understanding Mixed Emotions are Associated with High Callous-Unemotional Traits. ( 27100725 )
2017
44
Trait and state variance in oppositional defiant disorder symptoms: A multi-source investigation with Spanish children. ( 27148784 )
2017
45
Predicting Depression and Anxiety from Oppositional Defiant Disorder Symptoms in Elementary School-Age Girls and Boys with Conduct Problems. ( 27209374 )
2017
46
Child Personality Accounts for Oppositional Defiant Disorder Comorbidity Patterns. ( 27233508 )
2017
47
Sex Differences in the Prevalence of Oppositional Defiant Disorder During Middle Childhood: a Meta-Analysis. ( 27282758 )
2017
48
The Longitudinal Effects of Oppositional Defiant Disorder Symptoms on Academic and Occupational Functioning in the Transition to Young Adulthood. ( 27469319 )
2017
49
Factors related to the comorbidity between oppositional defiant disorder and anxiety disorders in preschool children. ( 27575516 )
2017
50
Innocent or Intentional?: Interpreting Oppositional Defiant Disorder in a Preschool Mental Health Clinic. ( 27761690 )
2017

Variations for Oppositional Defiant Disorder

ClinVar genetic disease variations for Oppositional Defiant Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 46;XY;t(2;11)(q31;q13.5)pat Translocation Uncertain significance
2 46;XY;t(4;7)(q31;q22)dn Translocation Uncertain significance
3 46;XX;t(2;5)(q33;p15.3) Translocation Uncertain significance

Expression for Oppositional Defiant Disorder

Search GEO for disease gene expression data for Oppositional Defiant Disorder.

Pathways for Oppositional Defiant Disorder

Pathways related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.71 COMT DRD4 MAOA SLC6A3
2
Show member pathways
12.68 COMT MAOA SLC6A3 SLC6A4
3 12.27 COMT DBH TPH2
5 11.87 MAOA SLC6A4 TPH2
6 11.79 SLC6A2 SLC6A3 SLC6A4
7
Show member pathways
11.62 COMT SLC6A2 SLC6A4
8 11.6 MAOA SLC6A4 TPH2
9
Show member pathways
11.15 DBH TPH2
10 10.88 MAOA SLC6A4 TPH2
11 10.86 DBH SLC6A2
12
Show member pathways
10.73 DBH MAOA SLC6A2 SLC6A3 SLC6A4 TPH2
13
Show member pathways
10.69 COMT MAOA SLC6A3 SLC6A4
14
Show member pathways
10.67 COMT DBH MAOA
15
Show member pathways
10.58 COMT MAOA
16 10.55 COMT MAOA

GO Terms for Oppositional Defiant Disorder

Cellular components related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of presynaptic membrane GO:0099056 9.26 SLC6A3 SLC6A4
2 integral component of postsynaptic membrane GO:0099055 9.16 SLC6A3 SLC6A4
3 membrane raft GO:0045121 9.13 SLC6A2 SLC6A3 SLC6A4
4 neuron projection GO:0043005 8.92 SLC6A2 SLC6A3 SLC6A4 TPH2

Biological processes related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.71 DBH DRD4 SLC6A2
2 response to drug GO:0042493 9.67 COMT SLC6A2 SLC6A3 SLC6A4
3 response to estrogen GO:0043627 9.56 COMT TPH2
4 social behavior GO:0035176 9.55 DRD4 SLC6A4
5 response to amphetamine GO:0001975 9.52 DBH DRD4
6 dopamine metabolic process GO:0042417 9.51 COMT DRD4
7 neurotransmitter biosynthetic process GO:0042136 9.49 SLC6A3 SLC6A4
8 catecholamine metabolic process GO:0006584 9.48 COMT MAOA
9 neurotransmitter catabolic process GO:0042135 9.46 COMT MAOA
10 regulation of dopamine metabolic process GO:0042053 9.43 DRD4 SLC6A3
11 neurotransmitter transport GO:0006836 9.43 SLC6A2 SLC6A3 SLC6A4
12 behavioral response to ethanol GO:0048149 9.4 DBH DRD4
13 response to pain GO:0048265 9.33 COMT DBH SLC6A2
14 fear response GO:0042596 9.32 DBH DRD4
15 monoamine transport GO:0015844 9.13 SLC6A2 SLC6A3 SLC6A4
16 dopamine catabolic process GO:0042420 8.92 COMT DBH MAOA SLC6A3

Molecular functions related to Oppositional Defiant Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.91 COMT DBH DRD4 SLC6A2 SLC6A3 SLC6A4
2 symporter activity GO:0015293 9.43 SLC6A2 SLC6A3 SLC6A4
3 dopamine binding GO:0035240 9.32 DRD4 SLC6A3
4 dopamine:sodium symporter activity GO:0005330 9.16 SLC6A2 SLC6A3
5 neurotransmitter:sodium symporter activity GO:0005328 9.13 SLC6A2 SLC6A3 SLC6A4
6 monoamine transmembrane transporter activity GO:0008504 8.8 SLC6A2 SLC6A3 SLC6A4

Sources for Oppositional Defiant Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....